INSMED INC

Insmed insider buying shows CEO Lewis William’s confidence in the bronchiectasis partnership—boosting investor sentiment and potential upside.

Insmed insider activity: CEO Lewis William’s recent 10 b5‑1 sales and buys reveal a disciplined, long‑term investment strategy—no red flag, just liquidity management.

Insmed insider sales show routine liquidity moves yet strong long‑term confidence. CFO Sara Bonstein’s May 2026 sell of 8,272 shares reflects tax‑and‑fee needs, not a warning—Insmed’s solid pipeline and positive market buzz keep it a compelling long…

Insmed CMO’s recent insider buy signals confidence in a turnaround, highlighting a trend of executive optimism amid volatile stock performance.

Insmed insider trades reveal a disciplined 10b5‑1 plan: CEO Lewis William buys low, sells high, boosting long‑term confidence while keeping short‑term volatility in check.

Insmed CEO’s April 2026 insider trades show disciplined buying at lows and selling near highs, hinting at confidence in rare‑disease pipeline growth.

Insmed CEO Lewis William’s latest insider trades show a strategic re‑balance at a deep discount, signalling confidence in the company’s long‑term biopharma prospects.

Insmed insider trading: Chief Legal Officer Michael Smith’s recent buying and selling reveals a 26 % stake increase, signalling confidence amid a 13.6 % weekly rally.

Insmed CEO Lewis William’s recent 10b5‑1 buys signal fresh confidence in the drug company’s upside—read why insider activity may hint at a rally and what to watch for.

Insmed insider sales spike: Dr. Martina Flammer sells 869 shares under a 10b‑5‑1 plan, amid a 4.47% weekly dip and negative earnings—what this means for investors.